Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.74Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 17, 2025
|% Change Since: -11.91%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development, potential strategic partnerships, and financial improvements, particularly with the expansion of HOPE Therapeutics. However, challenges remain due to the unsupportive capital market environment, low cash reserves, and regulatory complexities in clinic acquisitions. Despite these challenges, the positive developments and strategic initiatives outweigh the negatives.Company Guidance
During the NRx Pharmaceuticals 4Q and Full Year 2024 earnings call, the company provided detailed guidance on their strategic path forward. Over the past five months, they raised new capital, retired toxic debt, and began transitioning from a research-focused entity to a revenue-generating healthcare company. They announced the initiation of a New Drug Application (NDA) for NRX-100, a preservative-free intravenous ketamine, supported by data indicating over two years of room temperature shelf stability, with manufacturing capacity exceeding 1 million doses per month. NRx has received a strategic term sheet to acquire this product for over $300 million in total milestones and a double-digit royalty. Additionally, they are preparing an accelerated NDA filing for NRX-101, a combination of D-cycloserine and lurasidone, targeting a 2025 PDUFA date. NRx also launched HOPE Therapeutics, aimed at delivering clinical care through interventional psychiatry clinics, anticipating profitability by the end of 2025. Financially, the company reduced its operational loss by 33.5% to $18.5 million, with significant decreases in research and development expenses. Recent financings raised nearly $20 million, expected to sustain operations through 2025.Progress in Drug Development
NRx has made significant progress in drug development, including initiating the filing of a New Drug Application (NDA) for NRX-100, their preservative-free intravenous ketamine, and preparing an accelerated NDA filing for NRX-101. They have also developed a patentable version of pH-neutral ketamine, HTX-100, expected to begin human bioequivalence studies this year.
Potential Strategic Partnership
NRx received a strategic term sheet to acquire NRX-100 for more than $300 million in total milestones and a double-digit royalty, validating their drug development approach.
Financial Improvements
NRx Pharmaceuticals reduced its loss from operations by approximately $9.3 million, a 33.5% decrease, primarily driven by a reduction in research and development expenses.
HOPE Therapeutics Expansion
HOPE Therapeutics has signed nonbinding letters of intent to acquire three profitable interventional psychiatry clinics, with plans to acquire more in Florida and other locations. They aim to have 15 to 20 facilities by year-end 2025.
Financing and Capitalization
The company closed its third tranche of funding from Anson Funds, bringing the total financing to nearly $20 million, and anticipates that HOPE Clinics will be financed through non-dilutive means.
---
NRXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NRXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 17, 2025 | $2.35 | $2.05 | -12.77% |
| Nov 14, 2024 | $1.16 | $1.19 | +2.59% |
| Aug 13, 2024 | $1.90 | $1.86 | -2.11% |
| May 14, 2024 | $3.18 | $3.23 | +1.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NRX Pharmaceuticals (NRXP) report earnings?
NRX Pharmaceuticals (NRXP) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is NRX Pharmaceuticals (NRXP) earnings time?
NRX Pharmaceuticals (NRXP) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXP EPS forecast?
NRXP EPS forecast for the fiscal quarter 2025 (Q1) is -0.32.
---